Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | BP-5-087 is a STAT3 inhibitor, combining with BCR-ABL1 inhibition to overcome kinase-independent resistance in chronic myeloid leukemia. |
Molecular Weight | 770.69 |
Formula | C36H30F8N2O6S |
CAS No. | 1803281-30-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BP-5-087 1803281-30-2 CP690550 CP-690550 HCl tasocitinib. Trade name Xeljanz. Tofacitinib CP 690550 CP-690550 Tofacitinib hydrochloride inhibitor inhibit